The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review

Treatment of adults with newly diagnosed glioblastoma multiforme or anaplastic astrocytoma with surgery, gliadel wafers and limited field radiation plus concomitant temozolomide followed by adjuvant temozolomide

(2017) T. Ryken et al.   JOURNAL OF CLINICAL ONCOLOGY

Biodegradable Carmustine Wafers (Gliadel) Alone or in Combination with Chemoradiotherapy: The French Experience

(2010) Philippe Menei et al.   ANNALS OF SURGICAL ONCOLOGY

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience

(2010) Hans Christoph Bock et al.   NEUROSURGICAL REVIEW

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

(2009) Mary Lou Affronti et al.   CANCER

Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme

(2009) J. A. Quinn et al.   CLINICAL CANCER RESEARCH

Localized BCNU chemotherapy and the multimodal management of malignant glioma

(2009) Renato V. La Rocca et al.   CURRENT MEDICAL RESEARCH AND OPINION

Adding Biodegradable Carmustine Wafers before a Stupp Schedule Does Not Alter Outcome of Patients with High Grade Brain Tumor

(2009) G. Noel et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide

(2009) Martin Glas et al.   JOURNAL OF CLINICAL ONCOLOGY

Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation WithMGMTPromoter Methylation Status

(2009) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience

(2008) Frank J. Attenello et al.   ANNALS OF SURGICAL ONCOLOGY

Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years?

(2008) E. Anderson et al.   BRITISH JOURNAL OF NEUROSURGERY

Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience

(2008) Michael Sabel et al.   CURRENT MEDICAL RESEARCH AND OPINION

The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma

(2008) David J. Sher et al.   JOURNAL OF NEURO-ONCOLOGY

A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients

(2008) Edward Pan et al.   JOURNAL OF NEURO-ONCOLOGY

Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme

(2008) Matthew J. McGirt et al.   JOURNAL OF NEUROSURGERY